NBIX

#615
Neurocrine Biosciences, Inc. - Common Stock
158.3 0 USD
+1.22%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
158.30
158.30
Range Annuel
1.55
162.39
Changement quotidien
+1.22%
Changement Mensuel
+22.00%
Evolution sur 6 mois
+4.04%
Changement Annuel
+9.17%
Clôture Précédente
156.3 9
Open
158.3 0
Low
158.3 0
High
158.3 0
Volume
309
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 15.92 B
  • Employee 2 000
  • Founded 1992
  • CEO Kevin C. Gorman
  • Website www.neurocrine.com
  • Headquarter Delaware, United States
  • FIGI BBG000GJS7C1
  • Industry Fabricants de Médicaments — Spécialités et Génériques
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
30.37
ratio cours/chiffre d'affaires
5.08

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

Nouvelles